 |
|
|
 |
|
Rationale:
- Single-dose levonorgestrel, available as Plan B in the U.S., prevents 89% of pregnancies that would have otherwise occurred
and causes fewer side effects than the other postcoital contraception regimens.
- Ulipristal acetate is at least as effective as levonorgestrel and possibly more effective from 3 to 5 days after unprotected
intercourse. It is available only by prescription in the U.S. and is similar in cost to levonorgestrel.
|
|
Evidence:
- One review study concluded that as many as 22,000 rape-related pregnancies could be prevented yearly if all women who were
raped received prompt medical services and, if not already protected against pregnancy, were provided with emergency contraceptive
treatment (86).
- A review of eight efficacy studies estimates that the combination of ethinyl estradiol and a progestin, known as the Yuzpe
regimen, prevents approximately 74% of pregnancies that would have otherwise occurred (87).
- One randomized large-scale prospective clinical trial of 1955 women showed that the progestin-only regimen, available as Plan
B in the U.S., prevents significantly more than the Yuzpe regimen (88).
- A randomized, double-blind trial in 15 family-planning clinics in 10 countries involving 4136 healthy women found that the
progestin-only regimen (Plan B) may be given in a single dose of two pills with efficacy equal to the old two-dose plan (89).
- A prospective observational study of 111 women showed that emergency contraception retains its usual efficacy up to 120 hours
after coitus (89; 90).
- In a randomized, controlled trial, ulipristal acetate was slightly more effective at preventing pregnancy than levonorgestrel
in 2221 women up to 5 days after intercourse (1.4% vs. 2.2%; P=0.046) (91).
|
|
Comments:
- Plan B is currently FDA approved for postcoital contraception and is available without a prescription to persons aged 18 years
and older. All available evidence proves there are no untoward effects on the fetus should pregnancy occur despite postcoital
contraception. The common practice of obtaining written patient consent for these medications seems unwarranted.
|
| FAQs |
|
|
|
Carolyn J. Sachs, MD, MPH has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Deborah Korenstein, MD, FACP, Co-Editor, PIER, has no financial relationships with pharmaceutical companies, biomedical device
manufacturers, or health-care related organizations. Richard B. Lynn, MD, FACP, Co-Editor, PIER, has no financial relationships
with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
|
|
|
|
The information included herein should never be used as a substitute
for clinical judgment and does not represent an official position of
ACP. Because all PIER modules are updated regularly, printed web pages
or PDFs may rapidly become obsolete. Therefore, PIER users should
compare the date of the last update on the website with any printout
to ensure that the information being referred to is the most current
available.
|
PIER is copyrighted © 2012 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.
|
|
|